Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation

被引：34

作者：

Brenner, Talma ^{[1
,2
,3
]}

Nizri, Eran ^{[1
,2
,3
]}

Irony-Tur-Sinai, Michal ^{[1
,2
,3
]}

Hamra-Amitay, Yasmine ^{[1
,2
,3
]}

Wirguin, Itzhak ^{[4
]}

机构：

[1] Hadassah Univ Hosp, Dept Neurol, Lab Neuroimmunol, IL-91120 Jerusalem, Israel

[2] Hadassah Univ Hosp, Agnes Ginges Ctr Human Neurogenet, IL-91120 Jerusalem, Israel

[3] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel

[4] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Neurol, IL-84105 Beer Sheva, Israel

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2008年 / 201卷

关键词：

Acetylcholinesterase inhibitors; Myasthenia Gravis; Alzheimer's disease; Multiple Sclerosis; alpha-7-Acetylcholine receptors; Inflammation;

D O I：

10.1016/j.jneuroim.2008.05.022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The cholinergic network affects various cellular functions including neurotransmission, and immune reactions. In Myasthenia Gravis (MG), diagnosis and symptomatic therapy are based on cholinergic modulation by acetylcholinesterase inhibitors (AChEI). In Alzheimer's disease (AD) a neurodegenerative disorder associated with inflammatory pathology, cholinergic systems cell loss occurs early. Treatments with special AChEI enhance cholmergic transmission and may act as anti-inflammatory agent via immunocompetent cells expressing alpha-7 acetylcholine receptor (AChR). In Multiple Sclerosis (MS) an inflammatory T-cell-mediated disease, demyelination and neurodegeneration follow neuroinflammation. MS treatment includes anti-inflammatory and immunomodulatory drugs. AChEI can induce cholinergic up-regulation with subsequent effect on neuroinflammation via alpha-7-AChR expressing cells. These effects are additional to the cognitive benefit induced by AChEl. (C) 2008 Elsevier B.V All rights reserved.

引用

页码：121 / 127

页数：7

共 58 条

[1] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].

Aisen, PS ;

Schafer, KA ;

Grundman, M ;

Pfeiffer, E ;

Sano, M ;

Davis, KL ;

Farlow, MR ;

Jin, S ;

Thomas, RG ;

Thal, LJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826

[2] A randomized controlled trial of prednisone in Alzheimer's disease [J].

Aisen, PS ;

Davis, KL ;

Berg, JD ;

Schafer, K ;

Campbell, K ;

Thomas, RG ;

Weiner, MF ;

Farlow, MR ;

Sano, M ;

Grundman, M ;

Thal, LJ .

NEUROLOGY, 2000, 54 (03) :588-593

[3] Inflammation and Alzheimer's disease [J].

Akiyama, H ;

Barger, S ;

Barnum, S ;

Bradt, B ;

Bauer, J ;

Cole, GM ;

Cooper, NR ;

Eikelenboom, P ;

Emmerling, M ;

Fiebich, BL ;

Finch, CE ;

Frautschy, S ;

Griffin, WST ;

Hampel, H ;

Hull, M ;

Landreth, G ;

Lue, LF ;

Mrak, R ;

Mackenzie, IR ;

McGeer, PL ;

O'Banion, MK ;

Pachter, J ;

Pasinetti, G ;

Plata-Salaman, C ;

Rogers, J ;

Rydel, R ;

Shen, Y ;

Streit, W ;

Strohmeyer, R ;

Tooyoma, I ;

Van Muiswinkel, FL ;

Veerhuis, R ;

Walker, D ;

Webster, S ;

Wegrzyniak, B ;

Wenk, G ;

Wyss-Coray, T .

NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421

[4] Are there protective treatments for cognitive decline in MS? [J].

Amato, MP ;

Portaccio, E ;

Zipoli, V .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 245 (1-2) :183-186

[5]

[Anonymous], 1992, MUSCLE NERVE, V15, P229

[6] Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase [J].

Argov, Z. ;

Mckee, D. ;

Agus, S. ;

Brawer, S. ;

Shlomowitz, N. ;

Ben Yoseph, O. ;

Soreq, H. ;

Sussman, J. D. .

NEUROLOGY, 2007, 69 (07) :699-700

[7]

ARGOV Z, 1994, HDB MYASTHENIA GRAVI, P295

[8] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[9] Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].

Barnes, PJ ;

Larin, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071

[10] Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease [J].

Bjartmar, C ;

Wujek, JR ;

Trapp, BD .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) :165-171

← 1 2 3 4 5 6 →